Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icapamespib in recurrent malignant glioma
NCT04782609Phase 1Terminated
- Sponsor
- Samus Therapeutics
- Start
- Dec 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Icapamespib in malignant glioma, glioblastoma multiforme (GBM) and astrocytoma (2 arms), sponsored by Samus Therapeutics. Primary endpoints: Incidence and severity of adverse events up to 6 months, Maximum Tolerated Dose up to 6 months and 2 more. Started Dec 2021; status: terminated.
02
Drugs
Icapamespib
03
Conditions
malignant gliomaglioblastoma multiforme (GBM)astrocytoma
Beyond the preview
Go deeper on NCT04782609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782609.